Quick Takeaways
- VANGUARD GROUP INC filed SCHEDULE 13G/A for Crinetics Pharmaceuticals Inc Common Stock (CRNX).
- Disclosed ownership: 9.8%.
- Date of event: 31 Dec 2024.
VANGUARD GROUP INC - 31 Dec 2024 SCHEDULE 13G/A Report for Crinetics Pharmaceuticals Inc Common Stock (CRNX)
- Filing Manager
- VANGUARD GROUP INC
- Reporting Manager
- The Vanguard Group
- Symbol
- CRNX
- Shares outstanding
- 92,748,888 shares
- Disclosed Ownership
- 9,089,391 shares
- Ownership
- 9.8%
- Form type
- SCHEDULE 13G/A
- Filing time
- 30 Jan 2025, 21:33:19 UTC
- Date of event
- 31 Dec 2024
- Next filing
- 07 Apr 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"VANGUARD GROUP INC disclosed 9.8% ownership in Crinetics Pharmaceuticals Inc Common Stock (CRNX) on 31 Dec 2024."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 30 Jan 2025, 21:33.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (1)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| The Vanguard Group | 9.8% | 9,089,391 | 0 | 164,723 | Ashley Grim | Head of Global Fund Administration |